WeVote
Log In

Bill

Bill

A 7953

Provides for coverage of screenings for elevated lead levels

2025 Regular Session Introduced by Phara Souffrant Forrest

Bill A 7953 mandates insurance coverage for lead level screenings, focusing on children under six, to improve early detection and reduce lead poisoning risks.

REFERRED TO INSURANCE
0
WeVote Research Nonpartisan
Bill Summary · A 7953

Summary of Bill A 7953

Bill Number: A 7953
Title: Provides for coverage of screenings for elevated lead levels
Status: Referred to Insurance
Introduced: April 16, 2025
Classification: Bill

Purpose and Intent

Bill A 7953 aims to enhance public health by ensuring that screenings for elevated lead levels in individuals, particularly children, are covered by insurance. The intent is to identify and address lead exposure early, thereby reducing the risk of lead poisoning and its associated health complications.

Key Provisions

  • Insurance Coverage: The bill mandates that health insurance plans provide coverage for screenings that test for elevated lead levels. This includes both routine screenings and those deemed medically necessary by healthcare providers.

  • Target Population: The primary focus is on children under the age of six, who are at the highest risk for lead exposure and its harmful effects. However, the bill may also extend coverage to other vulnerable populations as determined by healthcare professionals.

  • Screening Guidelines: The bill may establish specific guidelines for when screenings should be conducted, potentially aligning with recommendations from public health authorities.

Impact

  • Public Health Improvement: By facilitating access to lead level screenings, the bill aims to improve early detection of lead exposure, which can lead to timely intervention and treatment.

  • Insurance Providers: Health insurance companies will be required to adjust their policies to comply with the new coverage mandates, which may involve changes to premium structures or the inclusion of additional services.

  • Healthcare Providers: Medical professionals will need to be aware of the new coverage requirements to effectively advise patients on screening options and ensure that necessary tests are conducted.

Procedural Aspects

  • Legislative Process: As of April 16, 2025, the bill has been referred to the Insurance Committee for further consideration. The timeline for subsequent actions, including potential hearings or votes, will depend on the committee's schedule.

Related Bills

  • S 6795: A prior-session bill that may have addressed similar issues regarding lead screening and public health.
  • S 2334: A companion bill that likely mirrors the provisions of A 7953, indicating bipartisan support for the initiative.

This summary provides an overview of Bill A 7953, highlighting its purpose, key provisions, and potential impacts on public health and insurance practices. The bill represents a proactive approach to addressing lead exposure, particularly among vulnerable populations.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.